Repositioning Candidate Details
| Candidate ID: | R0732 |
| Source ID: | DB05199 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | LX1031 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | LX1031 is an orally-dosed drug candidate for irritable bowel syndrome and other gastrointestinal disorders. LX1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key control point for the regulation of peripheral serotonin levels. LX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system functions. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Irritable bowel syndrome (IBS) and other gastrointestinal disorders |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | LX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system functions. |
| Targets: | Tryptophan 5-hydroxylase 1 |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|